Watson to Present at 2013 Goldman Sachs Healthcare CEOs Unscripted:
A View from the Top
PARSIPPANY, N.J., Dec. 20, 2012 /PRNewswire/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief
Executive Officer, will provide an overview and update of the
Company's business at the 2013 Goldman Sachs Healthcare CEOs
Unscripted: A View from the Top conference on Thursday, January 3, 2013 at 1:45 pm EST at the Goldman Sachs Conference
Center in New York. The
presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at
http://ir.watson.com. The webcast can also be accessed at the
following URL:
http://cc.talkpoint.com/gold006/010313a_gm/?entity=1_434SLG2
An archived version will be available approximately one hour
after the live presentation ends and can be accessed at the same
locations for 90 days.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global,
integrated specialty pharmaceutical company focused on developing,
manufacturing and distributing generic, brand and biosimilar
products. The Company has global and U.S. headquarters in
Parsippany, New Jersey, USA, and
international headquarters in Zug, Switzerland.
Watson is the world's third-largest generics prescription drug
manufacturer, with more than 750 products marketed globally through
operations in more than 60 countries. Watson's global branded
pharmaceutical business develops and markets products principally
in Urology and Women's Health, and is committed to developing
and marketing biosimilars products in Women's Health, Oncology and
other therapeutic categories. In addition, Watson is the
fourth-largest U.S. generic pharmaceutical product distributor
through its Anda, Inc. business, and also develops and out-licenses
generic pharmaceutical products outside of the U.S. through its
Medis third-party business. Watson has announced that it will
adopt a new global name – Actavis – effective in 2013.
For press release and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watson.com.
CONTACTS:
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Charlie
Mayr
|
|
(862)
261-8030
|
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO
)
SOURCE Watson Pharmaceuticals, Inc.